Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexuprazan vs Lansoprazole for Prevention of NSAID-Induced Peptic Ulcer
NCT04784910Phase 3Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- May 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fexuprazan in peptic ulcer disease (PUD) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoint: Proportion of subjects who develop peptic ulcer by Week 24. Started May 2021; status: completed.
02
Drugs
fexuprazan
03
Conditions
peptic ulcer disease (PUD)
Beyond the preview
Go deeper on NCT04784910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04784910.